Compounded-peptide policy reaches White House OMB review (15 Oct); Hers adds women's hair-loss care in the UK (14 Oct)

The policy would let compounding pharmacies temporarily produce certain restricted peptides, including BPC-157, ahead of a permanent rule. It is the first substantive procedural step since the process stalled in July, when the PCAC recommended 6 of 7 peptides and the FDA did not formally adopt the recommendation. OMB review is mandatory for economically significant rules, and the next step is publication, possibly after revisions. The link to HIMS: on 22 Sep Politico became the first third party to confirm that HIMS was preparing to launch peptide products within the year, and today NBC again named HIMS and Noom as the leading telehealth players targeting the category. Peptides are the high-margin leg that could offset the fall in gross margin from 76% to 64% in Q2 (reported 10 Aug), which the company attributes to branded weight-loss products and international revenue. An opening regulatory path gives the HIMS peptide story a timeline. It cuts both ways, though. Citeline/Pink Sheet reports that internal FDA staff raised safety concerns, yet the policy went ahead. HIMS is also a corporate sponsor of the MAHA movement (per the 22 Sep record). Paying for access to regulators while benefiting from their agency's green light on peptides is a governance and reputation thread that is thickening in parallel. (2) On 14 Oct Hers added clinician-led hair-loss care for women in the UK (Hers Hair, PRNewswire UK): an online assessment followed by a personalised prescription plan. This is separate from the 13 Oct rebrand of Juniper as Hers in Australia. The HIMS newsroom post 'Innovating for Her' (14 Oct) presents the UK as another step in taking women's health international. Hims & Hers already operates in the UK, Australia, Canada and Germany, and Hers already sells weight management in the UK. The launch continues the global integration that followed the Eucalyptus acquisition (worth up to $1.15 billion, agreed in February 2026 and closed in June 2026), expanding the women's health offer in markets where the group already operates. The read should stay restrained: this is a product launch, not yet validated by segment revenue, and it does not change unit economics. The next hard proof point is still Q3 earnings on 9 Nov, about 3 weeks away: can 38% year-on-year revenue growth turn into a step-up in profit and better unit economics? The core tension is unchanged, and the risk/reward still argues for caution.